Position in AZN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$258,851,052
New position
Shares Held
1,312,499
first reported quarter
Ownership
0.085%
of shares outstanding
% of Portfolio
0.42%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 98.23017008012958.ToString("F0")%
Shared 0.ToString("F0")%
None 1.769829919870415.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026NATIXIS ADVISORS, LLC holds $2,890,133,285 across 14 Drug Manufacturers - General names. AZN ranks #6 (9.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
780,730 | $718,092,031 | |
| 2 | JNJ |
Johnson & Johnson
|
1,744,076 | $426,321,937 | |
| 3 | MRK |
Merck & Co., Inc.
|
2,970,290 | $357,296,184 | |
| 4 | NVS |
Novartis AG
|
2,236,156 | $341,572,828 | |
| 5 | ABBV |
AbbVie Inc.
|
1,313,168 | $285,600,908 | |
| 6 | AZN |
Astrazeneca PLC
This page
|
1,312,499 | $258,851,052 | |
| 7 | AMGN |
Amgen Inc
|
392,002 | $137,925,903 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
951,907 | $132,667,278 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $258,851,052 | 1,312,499 | Shares | Defined | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||